Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial

The Lancet Oncology
Daniel P PetrylakKarim Fizazi

Abstract

Patients with metastatic castration-resistant prostate cancer have few treatment options. We investigated the safety and efficacy of lenalidomide, an immunomodulatory agent with anti-angiogenic properties, in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. In this randomised, double-blind, placebo-controlled, phase 3 study, we randomly assigned chemotherapy-naive patients with progressive metastatic castration-resistant prostate cancer in a 1:1 ratio to receive docetaxel (75 mg/m(2)) on day 1 and prednisone (5 mg twice daily) on days 1-21 and either lenalidomide (25 mg) or placebo once daily on days 1-14 of each 21 day treatment cycle. Permuted block randomisation was done with an interactive voice response system and stratified by Eastern Cooperative Oncology Group performance status, geographic region, and type of disease progression. Clinicians, patients, and investigators were masked to treatment allocation. The primary endpoint was overall survival. Efficacy analysis was by intention to treat. Patients who received at least one dose of study drug were included in the safety analyses. This study is registered with ClinicalTrials.gov, number NCT00...Continue Reading

References

Nov 22, 2001·Journal of the National Cancer Institute·M E GrossmannD J Tindall
Oct 8, 2004·The New England Journal of Medicine·Ian F TannockUNKNOWN TAX 327 Investigators
Jan 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dominik R BertholdIan F Tannock
Oct 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Andrew J ArmstrongDaniel J George
Nov 18, 2008·Investigational New Drugs·Sharon L SanbornMatthew M Cooney
Aug 25, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kim N ChiElizabeth A Eisenhauer
Apr 13, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard I ScherGlenn Heller
Sep 16, 2011·Journal of the National Cancer Institute·Farshid DayyaniPaul G Corn
Jan 21, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nicolas IsambertVeronique Trillet-Lenoir
Mar 29, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William Kevin KellyEric J Small
Mar 15, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J FerlayF Bray
Apr 10, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Karim S FizaziJudd W Moul
Apr 10, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Emmanuel S Antonarakis, Mario A Eisenberger

❮ Previous
Next ❯

Citations

May 8, 2015·Cancer Investigation·Roberto PetrioliGiandomenico Roviello
Sep 8, 2015·Journal of Controlled Release : Official Journal of the Controlled Release Society·Ahmed M Al-AbdVladimir P Torchilin
Dec 15, 2015·Mayo Clinic Proceedings·Jong Chul Park, Mario A Eisenberger
Sep 15, 2015·Future Oncology·Amanda R HathawayGuru Sonpavde
Jul 29, 2015·Current Oncology Reports·Michael Hurwitz
Aug 13, 2015·Current Urology Reports·Martin SpahnR Jeffrey Karnes
Jul 18, 2016·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·R LorionJ Irani
Sep 23, 2016·International Journal of Molecular Sciences·Luis León-MateosLaura Muinelo Romay
Oct 11, 2016·Cancer Treatment Reviews·Mark C Markowski, Michael A Carducci
Nov 16, 2016·Indian Journal of Urology : IJU : Journal of the Urological Society of India·Benjamin A Teply, Ralph J Hauke
Jan 25, 2017·Nature Reviews. Urology·Antonello VecciaOrazio Caffo
Mar 10, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Susan HalabiEric J Small
Jul 13, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew SmithKarim Fizazi
Jul 13, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joshi J Alumkal, Tomasz M Beer
Apr 6, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rana R McKayMary-Ellen Taplin
Mar 10, 2017·Expert Review of Molecular Diagnostics·Michele ColicchiaR Jeffrey Karnes
Apr 29, 2015·Nature Reviews. Clinical Oncology·Bobby C Liaw, William K Oh
Jun 4, 2019·International Journal of Molecular Sciences·Zsombor Melegh, Sebastian Oltean
Nov 1, 2017·JCO Clinical Cancer Informatics·Fatemeh SeyednasrollahUNKNOWN Prostate Cancer DREAM Challenge Community
Mar 16, 2016·Current Opinion in Oncology·Lisa M CordesRavi A Madan
May 18, 2016·Anti-cancer Drugs·Carlo CattriniFrancesco Boccardo
Jan 18, 2017·Future Oncology·Suliman Boulos, Danish Mazhar
Dec 13, 2017·Expert Opinion on Biological Therapy·John C Henegan, Guru Sonpavde
Aug 28, 2020·Cancers·Chandrani SarkarDebanjan Chakroborty
Dec 14, 2018·Oncoimmunology·Lucillia BezuLorenzo Galluzzi
Dec 17, 2019·JCO Precision Oncology·Susan HalabiSheng Luo
Dec 24, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Susan HalabiWilliam Kevin Kelly

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

© 2022 Meta ULC. All rights reserved